# A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension

> **NCT00811018** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 1192 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Sitaxsentan

## Key facts

- **NCT ID:** NCT00811018
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-03
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 1192 (ACTUAL)
- **Why stopped:** This trial was prematurely terminated on Dec 9 2010 due to safety concerns, specifically emerging evidence of hepatic injury.
- **Last updated:** 2012-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00811018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00811018, "A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00811018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*